\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ abnormalities\\ noted\\ during\\ testicular\\ exam\\.\ \(0\)\
\-\ annual\\ followup\\ ultrasound\\.\ \(0\)\
\-\ ultrasound\\ of\\ the\\ bilateral\\ testes\\ demonstrates\\ multiple\\ 1\\-2\\ mm\\ hyperechoic\\ nonshadowing\\ foci\\ present\\ throughout\\ the\\ testicular\\ parenchyma\\.\ \(0\)\
\-\ testicular\\ microlithiasis\ \(11\)\
\-\ punctate\\ hyperechoic\\ foci\\:\\ \\(microlithiasis\\ ddx\\)\ \(0\)\
\-\ 1\\.\\ granulomatous\\ changes\\ \ \(1\)\
\-\ 2\\.\\ scar\\ \ \(1\)\
\-\ 3\\.\\ benign\\ adenomatoid\\ tumor\\ \ \(1\)\
\-\ 4\\.\\ hemorrhage\\ with\\ infarction\ \(1\)\
\-\ 5\\.\\ post\\-inflammatory\\ changes\ \(2\)\
\-\ 6\\.\\ large\\ calcifying\\ sertoli\\ cell\\ tumor\ \(0\)\
\-\ 36\\ year\\ old\\ male\\ with\\ chronic\\ testicular\\ pain\\ for\\ several\\ years\\.\\ requests\\ evaluation\\ for\\ pathology\\.\ \(0\)\
\-\ classic\\ testicular\\ microlithiasis\\ is\\ defined\\ as\\ greater\\ than\\ 5\\ hyperechoic\\ nonshadowing\\ foci\\ \\(in\\ one\\ image\\)\\ throughout\\ the\\ parenchyma\\ of\\ the\\ testes\\.\\ although\\ frequently\\ symmetric\\,\\ it\\ can\\ often\\ times\\ be\\ asymptomatic\\ and\\ seen\\ on\\ the\\ periphery\\ of\\ the\\ testis\\.\\ in\\ patients\\ where\\ less\\ than\\ 5\\ foci\\ are\\ present\\ per\\ image\\,\\ limited\\ microlithiasis\\ is\\ diagnosed\\.\\ \ \(0\)\
\-\ previously\\ it\\ was\\ thought\\ that\\ germ\\ cell\\ tumors\\ were\\ present\\ in\\ up\\ to\\ 40\\%\\ of\\ patients\\ with\\ microlithiasis\\ \\(ref\\ 1\\ and\\ 2\\)\\.\\ this\\ corresponded\\ to\\ approximately\\ 21\\ times\\ increased\\ risk\\ of\\ testicular\\ cancer\\.\\ due\\ to\\ these\\ limited\\ studies\\,\\ there\\ were\\ controversial\\ recommendations\\ to\\ perform\\ yearly\\ ultrasound\\ follow\\-up\\ examinations\\ in\\ these\\ patients\\.\\ these\\ studies\\ were\\ performed\\ with\\ small\\ patient\\ numbers\\ in\\ individuals\\ referred\\ for\\ ultrasound\\ due\\ to\\ identification\\ of\\ testicular\\ masses\\.\\ \ \(0\)\
\-\ more\\ recent\\ studies\\ \\(ref\\ 3\\ and\\ 4\\)\\ were\\ performed\\ with\\ much\\ larger\\ study\\ subjects\\ involving\\ all\\ patients\\ undergoing\\ testicular\\ ultrasound\\ for\\ any\\ reason\\.\\ they\\ have\\ demonstrated\\ less\\ risk\\ \\(8\\%\\)\\ of\\ testicular\\ neoplasms\\ in\\ patients\\ with\\ microlithiasis\\ than\\ previously\\ thought\\.\\ moreover\\,\\ with\\ an\\ average\\ follow\\-up\\ ultrasound\\ average\\ of\\ 42\\ months\\,\\ no\\ additional\\ tumors\\ were\\ identified\\ in\\ these\\ patients\\ \\(ref\\ 4\\)\\.\\ the\\ authors\\ of\\ these\\ studies\\ suggested\\ that\\ it\\ would\\ not\\ significantly\\ affect\\ mortality\\/morbidity\\ to\\ continue\\ annual\\ ultrasound\\ surveillance\\.\\ they\\ suggested\\ a\\ more\\ reasonable\\ approach\\ to\\ patients\\ with\\ limited\\/classic\\ microlithiasis\\ would\\ be\\ to\\ perform\\ annual\\ physical\\ exams\\ and\\ montly\\ self\\-exams\\.\\ \ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ 1\\.\\ backus\\,\\ et\\.al\\.\\,\\ radiology\\ 1994\\;\\ 192\\:781\\-785\\.\\ \\(42\\ patients\\)\\ \ \(0\)\
\-\ 2\\.\\ miller\\,\\ et\\.al\\.\\,\\ j\\ clin\\ ultrasound\\ 1996\\;\\ 24\\:197\\-202\\.\\ \ \(0\)\
\-\ 3\\.\\ bennett\\,\\ et\\ al\\.\\,\\ testicular\\ microlithiasis\\:\\ us\\ follow\\-up\\.\\ radiology\\.\\ 2001\\;218\\:359\\-363\\.\\ \ \(0\)\
\-\ 4\\.\\ middleton\\,\\ et\\ al\\.\\,testicular\\ microlithiasis\\:\\ prospective\\ analysis\\ of\\ prevalence\\ and\\ associated\\ tumor\\.\\ radiology\\ 2002\\;224\\:425\\-428\\.\\ \\(1079\\ patients\\,\\ 195\\ with\\ testicular\\ microlithiasis\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ microlithiasis\\:\\ 0\\.1508016845151676\ \(0\)\
\-\ testicular\\:\\ 0\\.1299170851888351\ \(0\)\
\-\ ultrasound\\:\\ 0\\.05007649550629735\ \(0\)\
\-\ patients\\:\\ 0\\.04914610220813391\ \(0\)\
\-\ ref\\:\\ 0\\.04476244223501272\ \(0\)\
\-\ et\\.al\\.\\:\\ 0\\.03810817844591797\ \(0\)\
\-\ foci\\:\\ 0\\.036227397008918964\ \(0\)\
\-\ nonshadowing\\:\\ 0\\.034685229406115764\ \(0\)\
\-\ annual\\:\\ 0\\.03172532541343143\ \(0\)\
\-\ hyperechoic\\:\\ 0\\.031646101049603664\ \(0\)\
\-\ studies\\:\\ 0\\.03152099671880652\ \(0\)\
\-\ al\\.\\:\\ 0\\.03016033690303352\ \(0\)\
\-\ these\\:\\ 0\\.027454872740220248\ \(0\)\
\-\ radiology\\:\\ 0\\.026751938791775575\ \(0\)\
\-\ testes\\:\\ 0\\.026418679116872946\ \(0\)\
\-\ average\\:\\ 0\\.024626553222110634\ \(0\)\
\-\ perform\\:\\ 0\\.024214792190312848\ \(0\)\
\-\ were\\:\\ 0\\.02395415230481384\ \(0\)\
\-\ suggested\\:\\ 0\\.021479557063268713\ \(0\)\
\-\ 42\\:\\ 0\\.02136731878634251\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.020592866603272163\ \(0\)\
\-\ times\\:\\ 0\\.02045772636792391\ \(0\)\
\-\ mortality\\/morbidity\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ limited\\/classic\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ backus\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ 192\\:781\\-785\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ 24\\:197\\-202\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ 218\\:359\\-363\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ 224\\:425\\-428\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ 1079\\:\\ 0\\.02005523763804087\ \(0\)\
\-\ \\;\\:\\ 0\\.020004159885951542\ \(0\)\
\-\ thought\\:\\ 0\\.019420822229037665\ \(0\)\
\-\ montly\\:\\ 0\\.019054089222958984\ \(0\)\
\-\ self\\-exams\\:\\ 0\\.019054089222958984\ \(0\)\
\-\ requests\\:\\ 0\\.01834376311813977\ \(0\)\
\-\ 195\\:\\ 0\\.01834376311813977\ \(0\)\
\-\ parenchyma\\:\\ 0\\.017972191068605772\ \(0\)\
\-\ limited\\:\\ 0\\.017807566770988038\ \(0\)\
\-\ post\\-inflammatory\\:\\ 0\\.017792791386499748\ \(0\)\
\-\ subjects\\:\\ 0\\.017792791386499748\ \(0\)\
\-\ previously\\:\\ 0\\.017727267902485418\ \(0\)\
\-\ calcifying\\:\\ 0\\.017342614703057882\ \(0\)\
\-\ et\\:\\ 0\\.017271103358628553\ \(0\)\
\-\ corresponded\\:\\ 0\\.016961995740521443\ \(0\)\
\-\ middleton\\:\\ 0\\.016961995740521443\ \(0\)\
\-\ 4\\.\\:\\ 0\\.016614715903213815\ \(0\)\
\-\ than\\:\\ 0\\.016585547073468696\ \(0\)\
\-\ numbers\\:\\ 0\\.016341466287975996\ \(0\)\
\-\ bennett\\:\\ 0\\.016341466287975996\ \(0\)\
\-\ sertoli\\:\\ 0\\.01608131686659865\ \(0\)\
\-\ moreover\\:\\ 0\\.01608131686659865\ \(0\)\
\-\ tumors\\:\\ 0\\.015850451148990127\ \(0\)\
\-\ miller\\:\\ 0\\.01584598308930402\ \(0\)\
\-\ throughout\\:\\ 0\\.015796283092839144\ \(0\)\
\-\ risk\\:\\ 0\\.015284971098069563\ \(0\)\
\-\ they\\:\\ 0\\.015204672229566944\ \(0\)\
\-\ would\\:\\ 0\\.01501712038726958\ \(0\)\
\-\ tumor\\:\\ 0\\.014757276308228233\ \(0\)\
\-\ 3\\.\\:\\ 0\\.014438884998225814\ \(0\)\
\-\ present\\:\\ 0\\.014296361140234673\ \(0\)\
\-\ less\\:\\ 0\\.014291061749741641\ \(0\)\
\-\ \\(\\:\\ 0\\.014268873604816998\ \(0\)\
\-\ yearly\\:\\ 0\\.014249372805538457\ \(0\)\
\-\ 1994\\:\\ 0\\.014249372805538457\ \(0\)\
\-\ it\\:\\ 0\\.01422850655209642\ \(0\)\
\-\ authors\\:\\ 0\\.01413450856940292\ \(0\)\
\-\ \\)\\:\\ 0\\.014094571696065285\ \(0\)\
\-\ recommendations\\:\\ 0\\.014024751130956416\ \(0\)\
\-\ reasonable\\:\\ 0\\.013919665663255684\ \(0\)\
\-\ prospective\\:\\ 0\\.013919665663255684\ \(0\)\
\-\ controversial\\:\\ 0\\.013818870615057524\ \(0\)\
\-\ adenomatoid\\:\\ 0\\.013722029348012385\ \(0\)\
\-\ 2\\.\\:\\ 0\\.013419477243458065\ \(0\)\
\-\ identification\\:\\ 0\\.013287731406126794\ \(0\)\
\-\ reason\\:\\ 0\\.013287731406126794\ \(0\)\
\-\ 1996\\:\\ 0\\.013209339558436473\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0131811810681363\ \(0\)\
\-\ image\\:\\ 0\\.0131811810681363\ \(0\)\
\-\ surveillance\\:\\ 0\\.013133360154321032\ \(0\)\
\-\ examinations\\:\\ 0\\.01298807496907922\ \(0\)\
\-\ prevalence\\:\\ 0\\.01298807496907922\ \(0\)\
\-\ testis\\:\\ 0\\.012850865460054995\ \(0\)\
\-\ clin\\:\\ 0\\.012423034049501819\ \(0\)\
\-\ 5\\:\\ 0\\.012346471221946485\ \(0\)\
\-\ punctate\\:\\ 0\\.012313276611055317\ \(0\)\
\-\ individuals\\:\\ 0\\.012313276611055317\ \(0\)\
\-\ affect\\:\\ 0\\.012157279323100918\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.012107396095156424\ \(0\)\
\-\ changes\\:\\ 0\\.012094064080173139\ \(0\)\
\-\ exams\\:\\ 0\\.01191736883309191\ \(0\)\
\-\ periphery\\:\\ 0\\.011783869521313451\ \(0\)\
\-\ performed\\:\\ 0\\.011765818919641081\ \(0\)\
\-\ 4\\:\\ 0\\.011757885951501458\ \(0\)\
\-\ 2002\\:\\ 0\\.01153674987055547\ \(0\)\
\-\ cell\\:\\ 0\\.011398719563365365\ \(0\)\
\-\ continue\\:\\ 0\\.011384755073026007\ \(0\)\
\-\ due\\:\\ 0\\.01126062791581649\ \(0\)\
\-\ 2001\\:\\ 0\\.011207042728272698\ \(0\)\
\-\ \\:\\:\\ 0\\.011163208059167063\ \(0\)\
\-\ ddx\\:\\ 0\\.011139390940153896\ \(0\)\
\-\ approach\\:\\ 0\\.01107354341649424\ \(0\)\
\-\ scar\\:\\ 0\\.011009406413029398\ \(0\)\
\-\ germ\\:\\ 0\\.010916220418010023\ \(0\)\
\-\ significantly\\:\\ 0\\.010797202882657238\ \(0\)\
\-\ neoplasms\\:\\ 0\\.010739778531634357\ \(0\)\
\-\ analysis\\:\\ 0\\.010739778531634357\ \(0\)\
\-\ 36\\:\\ 0\\.010575108471143808\ \(0\)\
\-\ more\\:\\ 0\\.010553957083023043\ \(0\)\
\-\ undergoing\\:\\ 0\\.010347026199215374\ \(0\)\
\-\ 6\\.\\:\\ 0\\.010252047728035632\ \(0\)\
\-\ granulomatous\\:\\ 0\\.010183137140092235\ \(0\)\
\-\ larger\\:\\ 0\\.010160587797960696\ \(0\)\
\-\ followup\\:\\ 0\\.010072395001412352\ \(0\)\
\-\ \\%\\:\\ 0\\.009843560658498804\ \(0\)\
\-\ much\\:\\ 0\\.009767175357048952\ \(0\)\
\-\ symmetric\\:\\ 0\\.009636700094396164\ \(0\)\
\-\ 21\\:\\ 0\\.009547551934786\ \(0\)\
\-\ j\\:\\ 0\\.009530102139173425\ \(0\)\
\-\ \\,\\:\\ 0\\.009357878808004995\ \(0\)\
\-\ per\\:\\ 0\\.00923541878699425\ \(0\)\
\-\ frequently\\:\\ 0\\.009144520087925816\ \(0\)\
\-\ 5\\.\\:\\ 0\\.009100295577885\ \(0\)\
\-\ defined\\:\\ 0\\.008890327571253118\ \(0\)\
\-\ 40\\:\\ 0\\.008876944688612774\ \(0\)\
\-\ us\\:\\ 0\\.00885039458546151\ \(0\)\
\-\ references\\:\\ 0\\.008772415395213859\ \(0\)\
\-\ pathology\\:\\ 0\\.008635551679314277\ \(0\)\
\-\ infarction\\:\\ 0\\.00862347764155084\ \(0\)\
\-\ where\\:\\ 0\\.008611462358461523\ \(0\)\
\-\ additional\\:\\ 0\\.008460362207777771\ \(0\)\
\-\ to\\:\\ 0\\.00843591325319479\ \(0\)\
\-\ classic\\:\\ 0\\.008084579947674251\ \(0\)\
\-\ referred\\:\\ 0\\.007961806033223806\ \(0\)\
\-\ greater\\:\\ 0\\.007925225574495064\ \(0\)\
\-\ 8\\:\\ 0\\.00788917915617123\ \(0\)\
\-\ mm\\:\\ 0\\.007758506559987667\ \(0\)\
\-\ diagnosed\\:\\ 0\\.007758506559987667\ \(0\)\
\-\ abnormalities\\:\\ 0\\.007750036102958559\ \(0\)\
\-\ identified\\:\\ 0\\.0075394247930526456\ \(0\)\
\-\ involving\\:\\ 0\\.007403474725934059\ \(0\)\
\-\ that\\:\\ 0\\.00728879372127814\ \(0\)\
\-\ in\\:\\ 0\\.007283408916004406\ \(0\)\
\-\ benign\\:\\ 0\\.007281605844526423\ \(0\)\
\-\ for\\:\\ 0\\.007201068134742865\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.007132326908632314\ \(0\)\
\-\ masses\\:\\ 0\\.007132326908632314\ \(0\)\
\-\ although\\:\\ 0\\.007125751310065688\ \(0\)\
\-\ recent\\:\\ 0\\.007093133453925425\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.007022855763397619\ \(0\)\
\-\ study\\:\\ 0\\.0069422996465678\ \(0\)\
\-\ cancer\\:\\ 0\\.006936210529295717\ \(0\)\
\-\ several\\:\\ 0\\.0067829452733886115\ \(0\)\
\-\ often\\:\\ 0\\.006732033453134944\ \(0\)\
\-\ any\\:\\ 0\\.006644037118697021\ \(0\)\
\-\ approximately\\:\\ 0\\.006527945250754526\ \(0\)\
\-\ be\\:\\ 0\\.006507440609105823\ \(0\)\
\-\ during\\:\\ 0\\.006456812962774835\ \(0\)\
\-\ years\\:\\ 0\\.006195662066712303\ \(0\)\
\-\ demonstrated\\:\\ 0\\.006191160450511031\ \(0\)\
\-\ evaluation\\:\\ 0\\.006128984681053846\ \(0\)\
\-\ all\\:\\ 0\\.0059677123195834335\ \(0\)\
\-\ chronic\\:\\ 0\\.0059431842787827155\ \(0\)\
\-\ months\\:\\ 0\\.005762818011580413\ \(0\)\
\-\ one\\:\\ 0\\.005717855267433689\ \(0\)\
\-\ up\\:\\ 0\\.005673696669269687\ \(0\)\
\-\ physical\\:\\ 0\\.005176556221188243\ \(0\)\
\-\ increased\\:\\ 0\\.005161690819258409\ \(0\)\
\-\ bilateral\\:\\ 0\\.005120537603245541\ \(0\)\
\-\ 1\\:\\ 0\\.005020558933233844\ \(0\)\
\-\ noted\\:\\ 0\\.0050010399714878855\ \(0\)\
\-\ associated\\:\\ 0\\.004978919905944943\ \(0\)\
\-\ 3\\:\\ 0\\.004940680312855653\ \(0\)\
\-\ small\\:\\ 0\\.00486067971452128\ \(0\)\
\-\ can\\:\\ 0\\.004785734203627332\ \(0\)\
\-\ exam\\:\\ 0\\.0046351455307396\ \(0\)\
\-\ large\\:\\ 0\\.004613685016866863\ \(0\)\
\-\ demonstrates\\:\\ 0\\.004608941238649842\ \(0\)\
\-\ have\\:\\ 0\\.004568982909543436\ \(0\)\
\-\ 2\\:\\ 0\\.0045434678926186325\ \(0\)\
\-\ multiple\\:\\ 0\\.004443965440689553\ \(0\)\
\-\ no\\:\\ 0\\.004249106917055812\ \(0\)\
\-\ seen\\:\\ 0\\.004169450901401704\ \(0\)\
\-\ male\\:\\ 0\\.0038153223157715386\ \(0\)\
\-\ as\\:\\ 0\\.0031915493972694514\ \(0\)\
\-\ there\\:\\ 0\\.0031400384110246635\ \(0\)\
\-\ not\\:\\ 0\\.003048934991955396\ \(0\)\
\-\ an\\:\\ 0\\.002917691022925259\ \(0\)\
\-\ of\\:\\ 0\\.002876637056740455\ \(0\)\
\-\ are\\:\\ 0\\.002876231784023708\ \(0\)\
\-\ is\\:\\ 0\\.002776744584615929\ \(0\)\
\-\ with\\:\\ 0\\.00260009280199755\ \(0\)\
\-\ pain\\:\\ 0\\.0025768102901993447\ \(0\)\
\-\ was\\:\\ 0\\.0024401914128733006\ \(0\)\
\-\ the\\:\\ 0\\.0023894938096922975\ \(0\)\
\-\ this\\:\\ 0\\.0023731783044793407\ \(0\)\
\-\ year\\:\\ 0\\.0023607537512911475\ \(0\)\
\-\ and\\:\\ 0\\.0022223334041014623\ \(0\)\
\-\ old\\:\\ 0\\.0021603323379314927\ \(0\)\
\-\ patient\\:\\ 0\\.002115041804731822\ \(0\)\
\-\ \\.\\:\\ 0\\.002103676213176076\ \(0\)\
\-\ on\\:\\ 0\\.0017873852157171063\ \(0\)\
\-\ a\\:\\ 0\\.0009792587699224723\ \(0\)\
